Taking CAR-T Therapy to the Next Level is Part 2 of 3 of our most recent CAR-T series.  The dialogue is focused on moving from autologous to allogeneic approaches and from blood based cancer therapy to treating solid tumors.  The article also features a couple programs our panelists are actively working on that could change the outlook of CAR-T.


Panel Members

  • Bill Farley, VP of Business and Corporate Development, Sorrento Therapeutics
  • Anil Goyal, Chief Business Officer, MimiVax
  • Michael Catelani, Chief Operating and Financial Officer, Anixa Biosciences

Subscribe to Kineticos to receive weekly emails containing insightful content.